Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
GAITHERSBURG, Md. , Aug. 20, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced it has completed the sale of its drug product facility...
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
Active engagement with the World Health Organization , U.S. government and other global health leaders on critical efforts to prevent mpox disease transmission 50,000 doses of ACAM2000 ® ,...
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
Second Quarter 2024 Total Revenues of $254.7 million , above the prior guidance range Second Quarter 2024 Net Loss of $283.1 million and Adjusted EBITDA of $(10.1) million Updates FY 2024 guidance...
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
Customer-focused approach and continued investments in NARCAN ® Nasal Spray supply-readiness efforts help ensure opioid emergency preparedness GAITHERSBURG, Md. , Aug. 06, 2024 (GLOBE NEWSWIRE)...
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
GAITHERSBURG, Md. , July 31, 2024 (GLOBE NEWSWIRE) — Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the sale of RSDL ® (Reactive Skin Decontamination Lotion) kit to SERB...
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning GAITHERSBURG, Md. , July 24, 2024 (GLOBE...
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
GAITHERSBURG, Md. , July 23, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024 , at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Announces Shelf-Life Extension for NARCAN® Nasal Spray in Canada
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun...
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
GAITHERSBURG, Md. , July 09, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving its financial health, marked by robust cash...
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
GAITHERSBURG, Md. , July 02, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the...
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
GAITHERSBURG, Md. , June 20, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in...
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard of care for opioid overdose reversal in a community setting New topline survey findings reinforce the...